At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 174 enrolled
Drug / intervention
paroxetine +2 moredrug
Likely dose
paroxetine 15mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Parallel Randomized Double Blind Placebo Controlled Clinical Trial to Study the Efficacy and Safety of Paroxetine Daily Doses of 15 mg and 20 mg in the Treatment of Premature Ejaculation
In Brief
A Phase 3 clinical trial evaluating paroxetine and placebo for Premature Ejaculation. Completed, enrolled 174 participants across 2 sites.
Detailed Summary
As study to investigate the efficacy and safety of daily doses of paroxetine of 15 and 20 mg for the treatment of premature ejaculation
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPremature Ejaculation
CountriesMexico
Collaborators--
Timeline
Phase 3CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2008
Primary CompletionMar 2009
Study CompletionApr 2009
First PostedDec 2009
TodayJul 2026
First PostedDec 2, 2009
Enrollment StartAug 1, 2008
Primary CompletionMar 1, 2009
Study CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 16.6 years ago
Interventions
paroxetinedrug
daily dose of paroxetine 15mg for 12 weeks
paroxetinedrug
active daily treatment with paroxetine 20 mg
placebodrug
active daily treatment with placebo